MY01 Inc. Receives FDA Clearance for the MY01 Continuous Compartment Pressure Monitor as an Aid in Diagnosis of Compartment Syndrome
- MY01
MONTREAL, May 6, 2021 /PRNewswire/ – MY01’s device helps diagnose acute compartment syndrome (ACS), a relatively common and potentially lethal muscle condition notably suffered by Tiger Woods in his car accident last February. Because current diagnostic tools rely on a patient’s inherently subjective pain description, ACS diagnosis is often misdiagnosed or missed entirely and is the main cause of lost lawsuits against orthopedic surgeons in the U.S. Read more…
Related Reading
News / Regulatory Affairs
AdvaMed® Welcomes Senate Introduction of Bipartisan Medical Device Electronic Labeling Bill
May 14, 2026
Washington, D.C.—AdvaMed, the Medtech Association, the world’s biggest trade association representing medtech innovators, welcomed Senate introduction of the bipartisan Medical Device Electronic Labeling Act (S. 4519), which would allow medtech instructions for use to be provided electronically, with paper copies being available upon request.
News / Small Business
Esperto Medical™ Receives ARPA-H SBIR Award to Develop Continuous Wearable Blood Pressure Monitor
May 11, 2026
IRVINE, Calif., April 28, 2026 /PRNewswire/ — Esperto Medical™ today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) award from the Advanced Research Projects Agency for Health (ARPA-H) Scalable Solutions Mission Office to develop its next-generation continuous blood pressure monitoring solution. The project, titled “Continuous, Non-invasive, Calibration-Free Blood Pressure Monitoring by Resonance Sonomanometry,” will adapt Esperto’s proprietary resonance sonomanometry™ (RSM) technology into a wearable, wireless device suitable for home and ambulatory blood pressure monitoring.
News / Regulatory Affairs / Small Business
Bright Uro Receives FDA Clearance for Glean® Abdominal Sensor
May 8, 2026
IRVINE, Calif., May 7, 2026 /PRNewswire/ — Bright Uro, a medical device company with a mission to transform care for lower urinary tract dysfunction (LUTD) through innovations in urodynamics, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Glean® Abdominal Sensor. This new sensor expands the capabilities of the Glean® Urodynamics System to include multi-channel urodynamic studies. This comprehensive system enables wireless, catheter-free ambulatory urodynamics designed to support clinical decision making for patients with LUTD and other urological conditions.
News / Regulatory Affairs
i-GENTIC AI Expands GENIE to Enforce Full FDA Compliance Lifecycle for Life Sciences
May 4, 2026
PALO ALTO, CA, UNITED STATES, May 4, 2026 / EINPresswire.com / — Biopharma and medtech companies face a years-long process to get their products approved. Drug and device makers navigate a full spectrum of FDA and global regulatory frameworks to move innovation forward.
Blog / Coverage & Payment / Government & Legislative Affairs / Health Access / Regulatory Affairs
A Policy Win for Maternal Health Innovation Through FDA–CMS Collaboration
April 27, 2026
The United States faces a maternal health crisis demanding urgent action. The U.S. has the worst maternal outcomes among high income nations. Our maternal mortality rates far exceed peer countries’, despite the highest per capita health care spending. Protecting mothers and improving birth outcomes provides an important opportunity for bipartisan priority leadership.
Event / Regulatory Affairs
Compliance Considerations in an Active Deals Market for Medtech
June 17, 2026
12:00 PM – 1:00 PM
Join PwC to explore how compliance leaders can proactively support deal activity across the transaction lifecycle.
Event / Digital Health / Regulatory Affairs
AdvaMed® Cybersecurity Summit
November 10, 2026
Join cyber experts for the 2026 Cybersecurity Summit to address the latest industry issues and FDA requirements.
News / Regulatory Affairs / Small Business
Carbon Medical Technologies’ InjecSURE® Injection System Receives FDA 510(k) Clearance, Expanding CMT’s Portfolio of Urology Delivery Solutions
April 16, 2026
Saint Paul, MN – April 15, 2026. Carbon Medical Technologies, Inc. (CMT), a manufacturer of implantable medical devices and delivery systems utilizing proprietary technologies, is pleased to announce that its InjecSURE® Injection System has received clearance from the U.S. Food and Drug Administration (FDA) through the 510(k) pathway. This milestone marks the introduction of a new accessory system designed to support the delivery of syringe-based injectable materials into urethral tissues during cystoscopic procedures.